arGEN-X N.V. | Key People and Executives
Tim van Hauwermeiren
Chief Executive Officer & Executive Director
Anthony A. Rosenberg
Non-Executive Director
Peter K. M. Verhaeghe
Chairman
Pamela M. Klein
Independent Non-Executive Director
David L. Lacey
Independent Non-Executive Director
Joseph Donald deBethizy
Independent Non-Executive Director
Werner Lanthaler
Vice Chairman
Tim van Hauwermeiren
Chief Executive Officer & Executive Director
R. Keith Woods
Chief Operating Officer
Eric Castaldi
CFO & Principal Accounting Officer
Nicolas Leupin
Chief Medical Officer
Hans J. W. de Haard
Chief Scientific Officer
Debbie Allen
Senior Vice President-Business Development
Torsten Dreier
Chief Development Officer
Anthony A. Rosenberg
Non-Executive Director
Rebecca Rupert
Vice President-Marketing
Joke Comijn
Director-Communications & Investor Relations
Dirk Beeusaert
General Counsel
Peter K. M. Verhaeghe
Chairman
Pamela M. Klein
Independent Non-Executive Director
David L. Lacey
Independent Non-Executive Director
Joseph Donald deBethizy
Independent Non-Executive Director
Werner Lanthaler
Vice Chairman
| Address |
Willemstraat 5
Breda Noord-Brabant 4811 AH
Netherlands
|
|
Employees
|
- |
| Website |
http://www.argen-x.com |
| Updated |
07/08/2019 |
| argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia. It operates through the following geographical segments: Netherlands, Belgium, Germany, Denmark, Switzerland, United States, and Luxemburg. |
